Revel Bikes Gets Back to Roots with Hiring of Original Designer
Revel Bikes Gets Back to Roots with Hiring of Original Designer originally appeared on BikeMag.
Revel Bikes surprised and thrilled the mountain bike world when founder Adam Miller bought the troubled company at auction last month, and the good news keeps coming from the Carbondale, Colorado-based company.
Miller has brought on Mike Giese, Revel's original bike designer who will now serve as Director of Product Development and Creative Director.Giese worked with Miller back in the day from 2016 to 2018 to create Revel's iconic Rail, Rascal, and Ranger from concept to trail.
'Mike's the real deal,' said Miller in announcing Giese's return to Revel. 'He's got this rare combo of incredible engineering talent, insane bike handling skills, and an eye for design that's unmatched. It's wildly awesome to get to work with him again.'
Giese's frame designs, coupled with Chris Canfield's CBF suspension platform, created bikes that racked up awards and created devoted Revel riders.
After helping establish Revel, Giese went on to help develop new carbon bikes and components. He brings that experience back to Revel now with plans for exciting new builds, Miller says.
'Mike was a big part of why Revel clicked right from the start," Miller said. "Getting to build the next chapter together is something we're all really stoked about.'
'I am beyond excited for this next chapter with Revel Bikes,' Giese said. 'After working with Adam and team to design the original Rail, Rascal and Ranger, I am looking forward to joining the Revel Bikes team to lead product strategy, design and development for the next generation of bikes, and for the next generation of the brand.'
Revel has shifted to a direct-to-consumer model focused on making the high-quality bikes sans the middle markup. Customers can buy complete bikes and frames directly through Revel's website, and Revel ships globally. Revel also support custom builds through local bike shop dealers with their frame-only program.
From a serious question as to whether or not Revel would survive at all to the news that it's getting back to its small company, bike-loving roots, the mountain bike world has reason to be excited about the rebirth of Revel.
'Now, it is time to put the foot on the gas and design some insane new bikes, Giese said. 'Let the good times roll!'
This story was originally reported by BikeMag on Jun 3, 2025, where it first appeared.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
10 minutes ago
- Forbes
Escaping The Pig Butcher: Avoiding The Online Scam Stealing Billions
Pig butchering has conned billions of dollars from victims worldwide. The New York Post recently reported that the Cambodian-based Huione Group gang has reaped over $4 billion between August 2021 and January 2025. To some, pig butchering is nothing more than requesting a special cut at the meat market. Unfortunately, it's become a notorious form of cybercrime that causes complete financial devastation for its victims. Pig butchering (Sha Zhu Pan, which translates to 'killing pig plate') has a far more nefarious meaning. The Department of Financial Protection & Innovation defines pig butchering as a 'form of investment fraud in the crypto space where scammers build relationships with targets through social engineering and then lure them to invest crypto in fake opportunities or platforms created by the scammer.' Pig butchering has conned billions of dollars from victims worldwide. The New York Post recently reported that the Cambodian-based Huione Group gang has reaped over $4 billion between August 2021 and January 2025 alone. There are a few things to watch out for to avoid being lured into such extortion schemes. Often, they target seniors and other populations less familiar with cybercrime. According to The National Council on Aging, such scams often start with receiving a message out of the blue claiming to mistake you for someone else or having online profile pictures that look like a model. It's really important not to respond or send money to random people who contact you online, no matter how compelling their story is. Scammers are dependent upon gaining your trust, and a sympathetic or catchy story is a great way to do that. Another big warning sign is getting messages via SMS or social media that quickly redirect you to chat on another platform like Telegram or WeChat, which are less regulated and moderated. They might convince you to invest a small amount of money, which is then returned to you at a bigger profit. Before too long, the amounts of money being requested increase by leaps and bounds. A recent story out of Ohio details how an initial request for $10,000 quickly turned into a request for $500,000 to unlock any profits that were made. Even more appalling, the scammer requested the victim to 'go to a loan shark' to get the funds! In 2024, Meta removed 'over 2 million accounts' suspected of running crypto investment scams like pig butchering. Companies are starting to do more to combat pig butchering, but it's still a very real problem. A big step in their effort to keep people from falling for these scams is raising awareness through public posts broadcasting safety tips. They recently started rolling out warnings in Facebook Messenger and Instagram DMs tipping users off to 'potentially suspicious interactions or cold outreach from people you don't know', which is a good start. Banks are also beginning to require customers to acknowledge the dangers of scams when transferring money by ACH, Zelle, and wire. If you think you've been a victim of pig butchering, it's very important to both contact your bank and file a fraud report with the Federal Trade Commission. The sooner you report an incident, the more that can be done to help you potentially recover any lost funds. A recent blog from Norton advises victims to keep track of information, including 'messages, transaction records, and scammer contact information,' to better help authorities combat fraud. Although pig-butchering is an online scam that isn't going away anytime soon, the public can better protect themselves by being more aware of the warning signs and consequences of being involved in such a scheme. It reminds one of the classic saying, 'If it sounds too good to be true, it probably is!'
Business Journals
33 minutes ago
- Business Journals
Jacksonville-based Fidelity National eyes Nevada incorporation
Fidelity National Financial, a major Jacksonville-based company, is taking steps that could lead to a significant change in its corporate structure.
Yahoo
34 minutes ago
- Yahoo
Sydnexis Announces European Commission Approval of SYD-101, the First and Only Pharmaceutical Treatment for Slowing the Progression of Pediatric Myopia
Exclusive-Licensing Partner Santen Will Commercialize SYD-101 Under the Brand Name Ryjunea® in the European Union DEL MAR, Calif., June 05, 2025--(BUSINESS WIRE)--Sydnexis, Inc., ( a pre-commercial stage biopharmaceutical company today announced that the European Commission (EC) has granted marketing authorization for SYD-101, the company's proprietary low-dose atropine formulation, for slowing the progression of pediatric myopia. As the first and only approved pharmaceutical treatment option to treat myopia progression in EU countries, this approval marks a significant advancement in pediatric eye care. The approval is backed by data from the STAR study, Sydnexis' pivotal Phase 3 clinical trial evaluating its proprietary low-dose atropine formulation to slow the progression of pediatric myopia and the risk of associated co-morbidities in children 3 to 14 years old at treatment initiation. "This marks a significant milestone for Sydnexis and, most importantly, for pediatric patients with progressive myopia, their families, and physicians as the first and only approved pharmaceutical treatment option in Europe," said Perry Sternberg, Chief Executive Officer of Sydnexis. "This approval is an endorsement of the potential benefit SYD-101 can provide to millions of patients globally and reinforces the critical importance of early intervention." The marketing approval from the EC follows the recent positive opinion from the Committee for Medicinal Products for Human Use (CHMP). Santen, a Japan-based company specialized in eye health, offering innovative products and services in over 60 countries worldwide, licensed the rights from Sydnexis to commercialize SYD-101 in the regions of Europe, Middle East, and Africa (EMEA) and will launch SYD-101 under the brand name Ryjunea. "The EU approval of SYD-101 is a recognition of the compelling safety and efficacy data generated from our landmark STAR study," said Patrick Johnson, Ph.D., President of Sydnexis. "This validates the potential benefit that SYD-101 can provide to pediatric myopes in Europe and we are excited about our continued interactions with the Food and Drug Administration (FDA) leading up to our October 23 PDUFA date." Myopia is the most common eye disease in children, impacting approximately one-third of children and adolescents worldwide. By 2050, global prevalence is projected to increase and affect more than 740 million children and adolescents and 5 billion people in total. Once considered a benign refractive condition, even at low levels, myopia is now associated with many serious irreversible sight-threatening co-morbidities later in life. "As a Pediatric Ophthalmologist with a rapidly growing number of myopia patients around the world, the EU approval of SYD-101 is truly exciting and it provides an important new tool for physicians to combat this global epidemic," said Dr. Donny Suh, Gavin Herbert Eye Institute, University of California at Irvine. "The benefits of low-dose atropine have long been recognized in the eye care community, but we now finally have an approved and thoroughly vetted treatment option. This marks a new era in our ability to slow the progression of myopia and protect the vision of millions of children worldwide." About Sydnexis, Inc.: Founded in 2014, Sydnexis, Inc. ( is a privately held, pre-commercial stage biopharmaceutical company based in San Diego, California. Sydnexis recently completed its three-year primary endpoint in the pivotal Phase 3 clinical trial evaluating its proprietary low-dose atropine formulation to slow progression of pediatric myopia and the risk of associated co-morbidities. The Phase 3 clinical trial is now completing the fourth-year randomized withdrawal for exploratory endpoints and third year results will be announced upon completion of the fourth year of the study. The company is venture-backed by four major investors: Visionary Ventures, RA Capital, Longitude Capital, and Bluestem Capital. View source version on Contacts For media inquiries, please contact: media@
